AbbVie’s Gonzalez Expects More PBM Deals To Come In HCV
This article was originally published in The Pink Sheet Daily
Executive Summary
The AbbVie CEO said his company and Gilead are just engaging in the normal market dynamics that occur when an entrenched product faces viable competition for the first time. Gilead’s formulary agreement for its HCV drugs with CVS quickly followed the rapid decision by Express Scripts to give preferred formulary status to AbbVie’s Viekira Pak.